Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23624143 | 0.86 | KMT2A (0.40) | ALDH1A1CA14HDAC6DPP4HDAC1 | |
| SCHEMBL6538877 | 0.86 | CA14 (0.39) | ALDH1A1CA14HDAC6DPP4HDAC1 | |
| SCHEMBL3020149 | 0.83 | CA14 (0.49) | ALDH1A1CA14HDAC6DPP4HDAC1 | |
| SCHEMBL956549 | 0.83 | ALDH1A1 (0.42) | ALDH1A1CA14HDAC6DPP4HDAC1 | |
| SCHEMBL15942130 | 0.82 | CA14 (0.38) | ALDH1A1CA14HDAC6DPP4HDAC1 | |
| SCHEMBL15694959 | 0.82 | CA14 (0.38) | ALDH1A1CA14HDAC6DPP4HDAC1 | |
| SCHEMBL15668049 | 0.82 | SSTR4 (0.41) | ALDH1A1CA14HDAC6DPP4HDAC1 | |
| SCHEMBL3024404 | 0.82 | CA14 (0.48) | ALDH1A1CA14HDAC6DPP4HDAC1 | |
| SCHEMBL7941742 | 0.81 | CA14 (0.37) | ALDH1A1CA14HDAC6DPP4HDAC1 | |
| SCHEMBL1440925 | 0.81 | ALDH1A1 (0.38) | ALDH1A1CA14HDAC6DPP4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250368649-A1 | TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2025-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250368649-A1 | TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS | KRAS, NRAS, HRAS | ALDH1A1 3283/4885CA14 3865/4885HDAC6 3350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.